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Under the coordination of the European Centre for 
Disease Prevention and Control (ECDC), the European 
Legionnaires’ disease Surveillance Network (ELDSNet) 
conducts surveillance of Legionnaires’ disease (LD) in 
Europe. Between 2011 and 2015, 29 countries reported 
30,532 LD cases to ECDC (28,188 (92.3%) confirmed 
and 2,344 (7.7%) probable). Four countries (France, 
Germany, Italy and Spain) accounted for 70.3% of all 
reported cases, although their combined popula-
tions represented only 49.9% of the study popula-
tion. The age-standardised rate of all cases increased 
from 0.97 cases/100,000 population in 2011 to 1.30 
cases/100,000 population in 2015, corresponding to an 
annual average increase of 0.09 cases/100,000 popu-
lation (95%CI 0.02–0.14; p = 0.02). Demographics and 
infection setting remained unchanged with ca 70% of 
cases being community-acquired and 80% occurring 
in people aged 50 years and older. Clinical outcome 
was known for 23,164 cases, of whom 2,161 (9.3%) 
died. The overall case fatality ratio decreased steadily 
from 10.5% in 2011 to 8.1% in 2015, probably reflect-
ing improved reporting completeness. Five countries 
(Austria, Czech Republic, Germany, Italy, and Norway) 
had increasing age-standardised LD notification rates 
over the 2011−15 period, but there was no increase in 
notification rates in countries where the 2011 rate was 
below 0.5/100,000 population.
Background
Legionnaires’ disease (LD) is a severe pneumonia 
caused by Gram-negative bacteria, Legionella spp., 
which are found in freshwater environments worldwide 
and tend to contaminate man-made water systems 
[1]. People are infected by inhalation of contaminated 
aerosols and person-to-person transmission is excep-
tional [2]. LD is notifiable in all 30 European Union and 
European Economic Area (EU/EEA) countries, which 
reported 5,500 to 6,500 LD cases annually between 
2005 and 2010 with annual age-standardised rates 
fluctuating around one LD case per 100,000 inhab-
itants [3]. This overall rate masked important dif-
ferences across countries, with rates far below the 
European average reported by eastern and south-east-
ern European countries [4]. The notification rate was 
higher in males and increased with age. Approximately 
70% of all reported cases were community-acquired, 
20% travel-associated and 10% healthcare-related [2].
Several factors could possibly contribute to an increase 
of notified LD cases in Europe from 2011 to 2015. 
Previous studies have suggested that environmental 
conditions, especially rainfall and temperature, can 
affect the incidence of sporadic community-acquired 
LD cases [5,6] and it has been predicted that climate 
change will result in increases in temperature and 
changes in rainfall in Europe [7]. Additionally, the pop-
ulation structure of the EU/EEA is changing, with an 
increasing proportion of older persons who are more at 
risk of LD. People aged 65 years and over accounted for 
16.4% of the total EU/EEA population in 2004 and for 
18.5% in 2014 [8]. Finally, surveillance of LD in some 
European countries may be improving, as suggested by 
an evaluation carried out in France [9].
The objective of this study was to describe the epi-
demiology of LD in the EU/EEA from 2011 to 2015 and 
identify potential changes or trends in LD notification.
Methods
Under the coordination of the European Centre for 
Disease Prevention and Control (ECDC), the European 
Legionnaires’ disease Surveillance Network (ELDSNet) 
conducts surveillance of LD in Europe. ELDSNet 
includes all 28 EU Member States, plus Iceland and 
Norway. Since 2010, nominated ELDSNet members 
in each of the participating countries have annually 
reported all LD cases that fulfil the EU case defini-
tion [10] to the European Surveillance System (TESSy) 
database hosted by ECDC. The EU case definition was 
amended in 2012 to the effect that probable cases 
should be reported with at least one positive laboratory 
test for a probable case. All cases reported during the 
years from 2011 to  2015 and meeting the 2012 EU/EEA 
case definition of confirmed and probable cases were 
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included in the analysis. This study excluded Croatia 
from the analysis, because it only started reporting LD 
in 2013.
Information retrieved from TESSy included age, sex, 
date of disease onset, probable setting of infection, 
cluster status, laboratory method used for diagnosis, 
pathogen and clinical outcome. This study used pop-
ulation denominator data provided by the Statistical 
Office of the European Union (Eurostat) for calculating 
rates [11].
Continuous variables were compared across strata 
with the Mann–Whitney U test. Categorical variables 
were compared using chi-squared or Fisher exact tests. 
Age-standardised rates (ASR) were calculated using 
the direct method and the average age structure of the 
EU/EEA population for the period 2000 to 2010. Crude 
and age-adjusted male-to-female rate ratios were cal-
culated. To test for trend, a linear regression was fitted 
to age-standardised notification rates over the 2011–15 
period [12]. Goodness of fit of linear regressions was 
assessed using F statistics. Stata software release 14 
(StataCorp. LP, US) was used for all data management 
and statistical analyses.
Results
Case classification and notification rate
Over the 2011–15 period, 29 countries reported 30,532 
LD cases to ECDC, of which 28,188 (92.3%) were con-
firmed cases and 2,344 (7.7%) probable cases. The 
proportion of confirmed cases increased from 90.6% in 
2011 to 93.3% in 2015. In 2011, fewer than 50% of cases 
reported by Latvia (38%), Poland (44%), and Romania 
(0%) were confirmed. These three countries had more 
than 70% of their cases confirmed in 2015. The annual 
number of reported cases ranged from 4,915 in 2011 to 
6,986 in 2015. The ASR increased from 0.97 cases per 
100,000 population in 2011 to 1.30 cases per 100,000 
population in 2015, which corresponds to an annual 
average increase of 0.09 cases per 100,000 popula-
tion (95% confidence interval (CI) 0.02–0.14; p = 0.02). 
(Figure 1).
Geographical distribution
Four countries (France, Germany, Italy and Spain) 
accounted for 70.3% of all reported cases, although 
their combined populations represented only 49.9% of 
the study population (Table 1)
Conversely, the 20 lowest reporting countries reported 
only 10.2% of all cases, although their combined popu-
lations represented 28.8% of the study population. 
Country-specific average ASR ranged from 0.01 cases 
per 100,000 population in Bulgaria and Romania to 
3.46 cases per 100,000 population in Slovenia (Figure 
2).
Denmark, Italy, and Slovenia had ASR above 2.00 cases 
per 100,000 population. Over the 2011–15 period, five 
countries had significant trends: ASR increased in 
Austria (0.16 additional cases per 100,000 popula-
tion each year, 95% CI: 0.00 to 0.32), Czech Republic 
(0.16, 95% CI: 0.05 to 0.28), Germany (0.06, 95% CI: 
0.01 to 0.12), Italy (0.15, 95% CI: 0.00 to 0.30), and 
Norway (0.15, 95%CI: 0.01 to 0.30). In Latvia, the ASR 
decreased by 0.29 cases per 100.000 each year (95%CI 
-0.57 to -0.02). Portugal and Slovenia observed the 
highest yearly ASR with 5.33 cases per 100,000 popu-
lation in 2014 and 4.98 cases per 100,000 population 
in 2015, respectively (Table 1).
Age and sex
Information on age was available for 30,462 (99.8%) 
cases, of which 24,353 (79.8%) were 50 years old or 
older (Table 2).
Notification rates increased with age in both sexes, 
peaking at 5.8 cases per 100,000 population in males 
aged 80 years or older (Figure 3).
LD was more common in males with a crude male-to-
female rate ratio of 2.6:1 (age-adjusted 2.9:1). This 
ratio, which was stable over the 2011–15 period, steeply 
increased with age from 1.5:1 below 20 years to 3.3 in 
those aged 40–49 years and then slowly decreased 
in older age groups (Figure 3). Age-adjusted male-to-
female rate ratio ranged from 1.1:1 in Slovakia to 5.0:1 
in Cyprus. At date of onset, females (median 66 years, 
interquartile ratio (IQR): 54–77) were older than males 
(median 61 years, IQR: 51–72) (p < 0.01).
Probable setting of infection
The probable setting of infection acquisition was known 
for 26,900 cases reported from 2011 to 2015. Of these, 
Figure 1
Age-standardised rate of Legionnaires’ disease per 100,000 



























This study excluded Croatia from the analysis, because it only 
started reporting Legionnaires’ disease in 2013.
3www.eurosurveillance.org
19,019 (70.7%) were reported as community-acquired, 
5,357 (19.9%) as travel-associated, 1,973 (7.3%) as 
healthcare-related and 551 (2.0%) as associated with 
other settings (Table 2). The distribution of cases by 
setting of acquisition of infection remained stable over 
the study period. Of 16 countries that reported at least 
80% of their cases with known probable setting of 
infection, the proportion of community-acquired cases 
ranged from 38.8% in Norway to 96.1% in Slovenia. 
Norway had the highest proportion of cases associated 
with a stay abroad (61.2%) while the same proportion 
was below 2% in Bulgaria, Italy, Latvia, and Spain.
Outcome
Clinical outcome was known for 23,164 cases, of which 
2,161 (9.3%) died (Table 2). The case fatality ratio did 
not differ significantly by sex (9.1% in males vs 9.9% in 
females, p = 0.06). Over the 2011−15 period, the overall 
case fatality ratio decreased continuously, from 10.5% 
in 2011 to 8.1% in 2015. Over the same time, the pro-
portion of cases reported with unknown outcome has 
continuously decreased from ca 30% in 2011 to 20% in 
2015, and the crude mortality rate fluctuated between 
0.07 and 0.09 deaths per 100,000 population.
Laboratory tests and pathogens
Over the 2011−15 period, 33,809 laboratory tests were 
recorded for the 30,532 reported LD cases, of which 
78.2% were urinary antigen tests (UAT), 10.8% cultures, 
6.8% PCR and the remaining 1.1% other tests. Eleven of 
the 29 reporting countries reported more than one lab-
oratory test for some of their cases. The proportion of 
cases diagnosed by UAT was 78.9% in 2011 and fluctu-
ated between 87.3% and 88.9% from 2012 to 2015. The 
proportion of culture-confirmed cases was stable over 
the period at ca 12%. The proportion of cases reported 
to have been diagnosed by PCR increased from 4.3% 
in 2011 to 10.5% in 2015. Conversely, whereas 5.5% of 
cases were ascertained on the basis of a single high 
titre of a specific serum antibody in 2011, this propor-
tion decreased to less than 2% in 2015. Similarly, the 
proportion of cases reported on the basis of a fourfold 
rise in titre decreased steadily from 1.6% in 2011 to 
0.5% in 2015. Only 17 cases (< 0.1%) were reported as 
diagnosed by direct immunofluorescence during the 
2011−15 period. Of the 3,645 culture-confirmed cases 
reported, 3,511 (96.3%) were due to Legionella pneu-
mophila, including 3,020 (82.9% of culture-confirmed 
Figure 2
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cases) due to L. pneumophila serogroup 1 (Table 3). 
This proportion was stable over the study period.
Clusters
Of the 21,717 cases reported with known cluster sta-
tus, 19,559 (90.1%) were reported as sporadic cases 
(Table 2). Over the study period, 19 countries reported 
2,158 cases as part of a cluster. Of these 2,158 cases, 
1,923 (89.1%) were reported by six countries (Germany, 
Italy, the Netherlands, Portugal, Spain, and the United 
Kingdom (UK)). Of the 2,090 clustered cases with 
known probable setting of infection, 1,050 (50.2%) 
were reported as community-acquired, 841 (40.2%) 
as travel-associated, 150 (7.2%) as healthcare-related 
and 49 (2.3%) as associated with other settings. Of 
the 2,158 clustered cases, 1,348 (62.5%) were reported 
with a cluster identifier. The five largest reported clus-
ters were in Portugal (403 cases in 2014 and 30 cases 
from 2011 to 2013), Spain (39 and 18 cases in 2012), 
and the UK (23 cases in 2012).
Discussion
After the peak observed in 2010, the LD notifica-
tion rate in the EU/EEA in 2011 returned to the lev-
els observed from 2005 to 2009, when one case per 
100,000 population was reported each year [3]. The 
reasons behind the unexpected increase observed in 
2010 were not investigated in all countries, but a study 
in the Netherlands strongly suggested an association 
with warm and wet weather during the summer [13]. 
Over the 2011−15 period, the EU/EEA age-adjusted noti-
fication rate steadily increased to reach 1.30 case per 
100,000 population in 2014−15, the highest rate ever 
observed. Active surveillance of legionellosis in the 
United States found a comparable incidence of 1.30 per 
100,000 population from 2011 to 2013, but included 
notifications of both LD and Pontiac fever [14]. The 
overall ASR increase in the EU/EEA over the 2009−15 
period would suggest an effect beyond demographic 
change. It is also possible that the study period was 
too short to detect the effect of an ageing population 
in Europe. This overall increase was probably mostly 
driven by increases observed in a few populous coun-
tries, such as Germany and Italy.
In the five countries with ASR increasing trend over the 
2011−15 period, the increase was progressive which 
would be consistent with an improvement in surveil-
lance, although our data cannot exclude an effect of 
weather conditions more favourable to the growth of 
Legionella in some regions during the study period. 
Such improvement has already been reported in Italy 
over the 2000−11 period [15]. In other countries with 
stable ASR, the increasing number of LD cases would 
be compatible with an effect of demographic change 
with increasing numbers of at-risk older people. In 
Latvia, the decreasing ASR may reflect an improvement 
in laboratory ascertainment with less reliance on sero-
logical testing [16] and an increasing use of UAT, which 
is more specific.
None of the countries with notification rates below 0.5 
cases per 100,000 population had substantially increas-
ing ASR over the period studied. Reasons behind this 
possible under-ascertainment are probably multiple 
and country-specific. A study using travel-associated 
Legionnaires’ disease case notification and tour-
ism denominator data strongly suggested substantial 
Figure 3
Notification rates of Legionnaires’ disease per 100,000 population by sex and age group and male-to-female rate ratio by age 
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under-ascertainment in Greece [17]. The report of the 
first cluster of travel-associated Legionnaires’ disease 
detected in Bulgarian residents pointed out the lack 
of diagnostic tests on site and the lack of requests for 
legionella microbiology from physicians [18]. Similarly, 
lack of awareness and underdiagnoses were reported 
in Poland [19]
From 2011 to 2015, large outbreaks of LD were docu-
mented in Germany, Portugal, Spain, and the UK [20-
24]. Our data captured some of these, such as the 
community outbreak that occurred in Vila Franca de 
Xira, Portugal in 2014 [23], the community outbreak 
in Edinburgh, UK in 2012 [21] or the travel-associated 
outbreak in Calp, Spain in 2012 [20]. With the notable 
exception of the Vila Franca de Xira outbreak, the num-
ber of cases reported associated with these clusters 
only accounted for a small proportion of the cases 
reported at the country level. Several small clusters 
(2–3 cases) of travel-associated cases were reported, 
which might reflect both a higher probably of cluster-
ing in a travel setting and a result of the near-real-time 
surveillance of travel-associated cases within ELDSNet 
[25].
The shape of the male-to-female rate ratio by age group 
is suggestive of a higher male bias among adults aged 
30–59 years. Given the severity of LD, differences in 
health-seeking behaviour between sexes are unlikely. 
This could be explained by behavioural differences 
between sexes across age groups, such as smok-
ing habits. Smoking prevalence is decreasing in most 
EU/EA countries among both sexes, with a steeper 
decrease in males [26]. Sex smoking differences are 
Table 1
Number of reported cases of Legionnaires’ disease and age-standardised rates per 100,000 population, by reporting country 
and year, European Union/European Economic Area, 2011–2015
Country
2011 2012 2013 2014 2015
Number ASR Number ASR Number ASR Number ASR Number ASR
Austria 96 1.12 104 1.22 100 1.13 133 1.48 160 1.79
Belgium 79 0.71 84 0.45 155 1.37 200 1.72 196 1.44
Bulgaria 0 0.00 0 0.00 1 0.01 1 0.01 1 0.01
Cyprus 1 0.13 7 1.01 6 0.76 6 0.80 2 0.25
Czech Republic 57 0.52 56 0.53 67 0.63 110 1.03 120 1.10
Denmark 123 2.20 127 2.29 113 2.02 158 2.76 185 3.24
Estonia 7 0.51 3 0.24 10 0.76 8 0.59 6 0.43
Finland 9 0.16 10 0.18 15 0.24 10 0.17 17 0.27
France 1,170 1.84 1,298 2.01 1,262 1.92 1,348 2.04 1,389 2.07
Germany 635 0.73 628 0.72 810 0.90 832 0.92 865 0.95
Greece 18 0.16 29 0.25 38 0.33 27 0.24 29 0.25
Hungary 37 0.36 33 0.32 29 0.29 32 0.32 58 0.56
Iceland 3 1.35 2 0.71 0 0.00 4 1.30 1 0.36
Ireland 6 0.18 15 0.44 14 0.39 8 0.20 11 0.30
Italy 1,021 1.56 1,346 2.04 1,363 2.04 1,510 2.21 1,556 2.23
Latvia 49 2.32 48 2.33 34 1.63 38 1.86 22 1.09
Lithuania 2 0.07 9 0.31 1 0.04 8 0.28 7 0.25
Luxembourg 6 1.20 5 1.04 7 1.27 5 0.91 5 0.91
Malta 9 2.07 4 1.04 2 0.35 9 1.79 6 1.38
The Netherlands 311 1.88 304 1.83 308 1.83 348 2.04 419 2.39
Norway 33 0.72 25 0.52 40 0.83 51 1.06 60 1.22
Poland 18 0.05 8 0.02 11 0.03 12 0.03 23 0.06
Portugal 89 0.82 140 1.28 94 0.85 588 5.33 145 1.30
Romania 1 0.00 3 0.02 1 0.00 1 0.00 5 0.03
Slovakia 7 0.13 4 0.08 6 0.12 14 0.26 14 0.27
Slovenia 44 2.14 81 3.84 77 3.62 59 2.76 106 4.98
Spain 706 1.52 972 2.07 815 1.72 925 1.78 1,024 2.12
Sweden 127 1.32 102 1.04 122 1.25 136 1.38 142 1.42
United Kingdom 251 0.41 401 0.66 331 0.54 370 0.59 412 0.65
EU/EEA 4,915 0.97 5,848 1.13 5,832 1.12 6,951 1.31 6,986 1.30
ASR: age-standardised rate; EEA: European Economic Area; EU: European Union.
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narrowing but consequences may only be perceived 
in future cohorts of LD cases. Exposure to other risk 
factors such as home plumbing work could be associ-
ated with sex and age [27]. Unfortunately, known risk 
factors for LD such as smoking or comorbidities are 
not collected as part of routine surveillance at EU/
EEA level. Such factors might partly explain sex, age 
or country differences with heterogeneous burden of 
chronic pulmonary disease across Europe [28]. In addi-
tion, a recent study carried out in New York suggested 
that occupation and other social determinants may 
also represent risks factors for LD [29]. Although only a 
few LD cases were under 20 years of age, LD should not 
be overlooked in children, especially those with under-
lying conditions such as cancer [30].
The decreasing case fatality ratio may suggest a report-
ing bias towards fatal outcomes in the past which is 
gradually being corrected by improved reporting com-
pleteness. The main demographic characteristics and 
probable settings of infection of LD cases remained 
unchanged during the study period and comparable to 
previous reports [3].
The landscape of laboratory tests used to diagnose 
LD has changed over the past years. If both UAT and 
culture have remained the most frequently used tests, 
the late 2000s have confirmed the rise of PCR and the 
inexorable decline of diagnosis by fourfold titre rise 
and single high titre in specific serum antibody [25]. 
The main limitation of UAT is its poor sensitivity to non-
L. pneumophila serogroup 1 strains [31]. The number 
Table 2




Number Percentage  (%)
All cases 30,532 100 1.21
Age group (years)
< 20 159 0.5 0.03
20–29 473 1.6 0.15
30–39 1,440 4.7 0.41
40–49 4,037 13.3 1.08
50–59 6,917 22.7 2.00
60–69 7,120 23.4 2.52
70–79 5,882 19.3 2.88
≥ 80 4,434 14.6 3.47
Unknown 70 NA NA
Sex
Male 21,618 71.1 1.75
Female 8,789 28.9 0.68
Unknown 125 NA NA
Probable setting of infection
Community 19,019 70.7 0.75
Travel abroad 3,098 11.5 NA
Domestic travel 2,259 8.4 NA
Nosocomial 1,322 4.9 NA
Other healthcare 651 2.4 NA
Other 551 2.0 NA
Unknown 3,632 NA NA
Cluster status
Sporadic cases 19,559 90.1 NA
Clustered cases 2,158 9.9 NA
Unknown 8,815 NA NA
Outcome
Alive 21,003 90.7 NA
Dead 2,161 9.3 0.09
Unknown 7,368 NA NA
NA: Not applicable.
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of culture-confirmed cases reported with an infection 
caused by other species should remind us the risk of 
an exclusive reliance on UAT.
Trends observed at national level may mask sub-
national disparities, especially in large countries. This 
has been documented in Italy where a study has sug-
gested higher under-reporting in central and southern 
regions compared with northern regions [15]. This anal-
ysis could not capture such heterogeneity, but these 
findings could be highly valuable for informing national 
policies.
These findings illustrate the added-value of the net-
work whose activities help ensure the collection of 
high-quality data. All reporting countries use the same 
reporting protocol and case definition. In addition, 
ELDSNet offers training and external quality assess-
ment (EQA) to improve laboratory capabilities.
Conclusion
The burden of LD appears to be growing in Europe and 
at least 450 people still die of LD each year in the EU/
EEA. The epidemiology is very similar to that observed 
in the United States, with a comparable notification 
rate and similar settings of infection. In countries with 
persistently low notification rates, ad hoc studies 
should identify reasons for under-ascertainment. All 
countries should endeavour to develop and maintain 
appropriate control measures in man-made water sys-
tems to prevent LD cases.
The European Legionnaires’ disease Surveillance Network
Daniela Schmid, Günther Wewalka (Austria); Olivier 
Denis, Stéphanie Jacquinet, Denis Piérard, Sophie Quoilin 
(Belgium); Iskra Tomova (Bulgaria); Despo Pieridou, Ioanna 
Gregoriou, Maria Koliou (Cyprus); Vladimir Drašar, Irena 
Martinkova (Czech Republic); Charlotte Kjelsø, Søren Anker 
Uldum (Denmark); Irina Dontsenko, Rita Peetso (Estonia); 
Sari Jaakola; Jaana Kusnetsov; Outi Lyytikäinen; Silja 
Mentula (Finland); Christine Campese, Sophie Jarraud, 
Agnes Lepoutre (France); Bonita Brodhun, Christian Lück 
(Germany); Georgia Spala (Greece); Ágnes Fehér, Ildikó 
Ferenczné Paluska (Hungary); Thorolfur Gudnason, Guðrún 
Sigmundsdóttir (Iceland); Mary Hickey, Tara Mitchell, 
Joan O’Donnell, Darina O’Flanagan (Ireland); Maria Grazia 
Caporali, Maria Luisa Ricci, Maria Cristina Rota (Italy); Antra 
Bormane, Jelena Galajeva, Oksana Savicka (Latvia); Migle 
Janulaitiene, Simona Zukauskaite-Sarapajeviene (Lithuania); 
Paul Reichert (Luxembourg); Jackie Maistre Melillo, Tanya 
Melillo Fenech, Graziella Zahra (Malta); Petra Brandsema, 
Ed IJzerman, Leslie Isken, Daan Notermans, (Netherlands); 
Dominique Caugant, Heidi Lange (Norway); Michal 
Czerwinski, Katarzyna Piekarska (Poland); Teresa Fernandes, 
Maria Teresa Marques (Portugal); Daniela Badescu, Gratiana 
Chicin (Romania); Danka Šimonyiová, Margita Špaleková 
(Slovak Republic); Maja Sočan, Darja Kese (Slovenia); Rosa 
Cano-Portero, Carmen Pelaz Antolin (Spain); Margareta 
Löfdahl (Sweden); Eleanor Anderson; Tim Harrison; Falguni 
Naik; Nick Phin; Kevin Pollock; Alison Potts; Elaine Stanford 
(United Kingdom)
Acknowledgements
This article is dedicated to Dr Georgia Spala, who sadly 
passed away shortly before the submission of this manu-
script. Her expertise and contribution in this field will be 
dearly missed. I would like to thank the ECDC ELDSNet team: 
Cátia Cunha, Birgitta de Jong, Lara Payne Hallström, Anna 
Renau-Rosell, and Emmanuel Robesyn. I would like to thank 





JB designed the study, ran the analysis and drafted the man-
uscript. The European Legionnaires’ Disease Surveillance 
Network contributed to the data collection, analysis and 
Table 3
Reported culture-confirmed cases of Legionnaires’ disease 
and Legionella pneumophila isolates by species and 








serogroup 1 3,020 82.9
serogroup 2 19 0.5
serogroup 3 101 2.8
serogroup 4 13 0.4
serogroup 5 19 0.5
serogroup 6 42 1.2
serogroup 7 9 0.2
serogroup 8 8 0.2
serogroup 9 5 0.1
serogroup 10 19 0.5
serogroup 11 3 0.1
serogroup 12 1 < 0.1
serogroup 13 2 0.1
serogroup 14 7 0.2
serogroup mixed 4 0.1
non-serogroup 1 7 0.2
serogroup unknown 232 6.4
L. anisa NA 2 0.1
L. bozemanii NA 15 0.4
L. cincinnatiensis NA 1 < 0.1
L. dumoffii NA 2 0.1
L. longbeachae NA 35 1.0
L. macaechernii NA 1 < 0.1
L. micdadei NA 12 0.3
L. sainthelensi NA 1 0.0
L. other species NA 27 0.7
L. species unknown NA 38 1.0
Total NA 3,645 100
This study excluded Croatia from the analysis, because it only 
started reporting on Legionnaires’ disease in 2013.
8 www.eurosurveillance.org
interpretation, and revised the manuscript, providing sub-
stantial intellectual input.
References
1. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires’ 
disease: 25 years of investigation.Clin Microbiol Rev. 
2002;15(3):506-26. DOI: 10.1128/CMR.15.3.506-526.2002 PMID: 
12097254
2. Correia AM, Ferreira JS, Borges V, Nunes A, Gomes B, 
Capucho R,  et al.  Probable Person-to-Person Transmission of 
Legionnaires’ Disease. N Engl J Med. 2016;374(5):497-8. DOI: 
10.1056/NEJMc1505356 PMID: 26840151
3. Beauté J, Zucs P, de Jong B, European Legionnaires’ Disease 
Surveillance Network. Legionnaires disease in Europe, 2009-
2010.Euro Surveill. 2013;18(10):20417.PMID: 23515061
4. Beauté J, Robesyn E, de Jong B, European Legionnaires’ 
Disease Surveillance Network. Legionnaires’ disease 
in Europe: all quiet on the eastern front?Eur Respir J. 
2013;42(6):1454-8. DOI: 10.1183/09031936.00089113 PMID: 
24293418
5. Sakamoto R. Legionnaire’s disease, weather and climate.
Bull World Health Organ. 2015;93(6):435-6. DOI: 10.2471/
BLT.14.142299 PMID: 26240466
6. Beauté J, Sandin S, Uldum SA, Rota MC, Brandsema P, 
Giesecke J, et al. Short-term effects of atmospheric pressure, 
temperature, and rainfall on notification rate of community-
acquired Legionnaires’ disease in four European countries. 
Epidemiol Infect. 2016;1-11. [Epub ahead of print].PMID: 
27572105
7. European Environment Agency (EEA). Climate change, 
impacts and vulnerability in Europe 2012 an indicator-
based report. Luxembourg: EEA; 2012. Available 
from: http://www.eea.europa.eu/publications/
climate-impacts-and-vulnerability-2012/at_download/file
8. Eurostat. Population structure and ageing - Statistics 
Explained. Luxembourg: Eurostat. [Accessed 21 Apr 2016]. 
Available from: http://ec.europa.eu/eurostat/statistics-
explained/index.php/Population_structure_and_ageing
9. Campese C, Jarraud S, Sommen C, Maine C, Che D. 
Legionnaires’ disease in France: sensitivity of the mandatory 
notification has improved over the last decade.Epidemiol 
Infect. 2013;141(12):2644-9. DOI: 10.1017/S0950268813000502 
PMID: 23481220
10. Commission of the European Communities. Commission 
Implementing Decision 2012/506/EU of 8 August 2012 
amending Decision 2002/253/EC laying down case definitions 
for reporting communicable diseases to the Community 
network under Decision No 2119/98/EC of the European 
Parliament and of the Council. Luxembourg: Official Journal of 
the European Union. Available from: http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=OJ:L:2012:262:0001:0057:EN:P
DF
11. Eurostat. Population on 1 January by age group and sex. 
Luxembourg: Eurostat. [Accessed 10 Aug 2016]. Available 
from: http://appsso.eurostat.ec.europa.eu/nui/show.
do?dataset=demo_pjangroup&lang=en
12. Boyle P, Parkin DM. Cancer registration: principles and 
methods. Statistical methods for registries. IARC Sci Publ. 
1991; (95):126-58.PMID: 1894318
13. Brandsema PS, Euser SM, Karagiannis I, Den Boer JW, Van 
Der Hoek W. Summer increase of Legionnaires’ disease 
2010 in The Netherlands associated with weather conditions 
and implications for source finding.Epidemiol Infect. 
2014;142(11):2360-71. DOI: 10.1017/S0950268813003476 PMID: 
24576486
14. Dooling KL, Toews K-A, Hicks LA, Garrison LE, Bachaus 
B, Zansky S,  et al.  Active Bacterial Core Surveillance for 
Legionellosis - United States, 2011-2013. MMWR Morb Mortal 
Wkly Rep. 2015;64(42):1190-3. DOI: 10.15585/mmwr.mm6442a2 
PMID: 26513329
15. Rota MC, Caporali MG, Bella A, Ricci ML, Napoli C. 
Legionnaires’ disease in Italy: results of the epidemiological 
surveillance from 2000 to 2011.Euro Surveill. 
2013;18(23):20497.PMID: 23787129
16. Rozentale B, Bormane A, Perevosčikovs J, Lucenko I, Brila A. 
Increase of cases of legionellosis in Latvia, 2011.Euro Surveill. 
2011;16(45):20009.PMID: 22114976
17. Beauté J, Zucs P, de Jong B. Risk for travel-associated 
legionnaires’ disease, Europe, 2009.Emerg Infect Dis. 
2012;18(11):1811-6. DOI: 10.3201/eid1811.120496 PMID: 
23092591
18. Tomova I, Marinov R, Maeva I. First cluster of travel-associated 
legionnaires’ disease detected in Bulgarian citizens.Euro 
Surveill. 2007;12(4):E070412.2.PMID: 17439804
19. Stypułkowska-Misiurewicz H, Czerwiński MA. Legionellosis 
in Poland in 2014.Przegl Epidemiol. 2016;70(2):203-7.PMID: 
27779835
20. Vanaclocha H, Guiral S, Morera V, Calatayud MA, Castellanos 
M, Moya V,  et al.  Preliminary report: outbreak of Legionnaires 
disease in a hotel in Calp, Spain, update on 22 February 2012. 
Euro Surveill. 2012;17(8):20093.PMID: 22401506
21. Irons JF, Dunn MJG, Kefala K, Thorn S, Lakha F, Caesar D,  et 
al.  The effect of a large Legionnaires’ disease outbreak in 
Southwest Edinburgh on acute and critical care services. 
QJM. 2013;106(12):1087-94. DOI: 10.1093/qjmed/hct167 PMID: 
23970183
22. Maisa A, Brockmann A, Renken F, Lück C, Pleischl S, Exner 
M,  et al.  Epidemiological investigation and case-control 
study: a Legionnaires’ disease outbreak associated with 
cooling towers in Warstein, Germany, August-September 2013. 
Euro Surveill. 2015;20(46):30064. DOI: 10.2807/1560-7917.
ES.2015.20.46.30064 PMID: 26607018
23. Shivaji T, Sousa Pinto C, San-Bento A, Oliveira Serra LA, 
Valente J, Machado J,  et al.  A large community outbreak of 
Legionnaires disease in Vila Franca de Xira, Portugal, October 
to November 2014. Euro Surveill. 2014;19(50):20991. DOI: 
10.2807/1560-7917.ES2014.19.50.20991 PMID: 25597540
24. Pelaz C, Cano R, Chico M, Asensio G, Bellido B, Iascu A, et 
al. A large community outbreak of Legionnaires´ disease in 
Manzanares, Ciudad Real, Spain. 4th ESGLI Conference; 2016; 
Amsterdam. Available from: http://www.iwcconferences.com/
wp-content/uploads/2016/10/Conference-book-ESGLI.pdf
25. European Centre for Disease Prevention and Control (ECDC). 
Legionnaires’ disease surveillance in Europe, 2014. Stockholm: 
ECDC; 2016. Available from: http://ecdc.europa.eu/en/
publications/Publications/legionnares-disease-europe-2014.
pdf
26. Organisation for Economic Co-operation and Development 
(OECD). Non-medical determinants of health. Paris: OECD. 
[Accessed 26 Oct 2016]. Available from: http://stats.oecd.org/
index.aspx?DataSetCode=HEALTH_LVNG
27. Straus WL, Plouffe JF, File TM, Lipman HB, Hackman BH, 
Salstrom SJ,  et al.  Risk factors for domestic acquisition 
of legionnaires disease. Ohio legionnaires Disease Group. 
Arch Intern Med. 1996;156(15):1685-92. DOI: 10.1001/
archinte.1996.00440140115011 PMID: 8694667
28. Begum M, Lewison G, Wright JSF, Pallari E, Sullivan R. 
European Non-Communicable Respiratory Disease Research, 
2002-13: Bibliometric Study of Outputs and Funding.PLoS One. 
2016;11(4):e0154197. DOI: 10.1371/journal.pone.0154197 PMID: 
27111670
29. Farnham A, Alleyne L, Cimini D, Balter S. Legionnaires’ disease 
incidence and risk factors, New York, New York, USA, 2002-
2011.Emerg Infect Dis. 2014;20(11):1795-802. DOI: 10.3201/
eid2011.131872 PMID: 25513657
30. Greenberg D, Chiou CC, Famigilleti R, Lee TC, Yu VL. Problem 
pathogens: paediatric legionellosis--implications for improved 
diagnosis.Lancet Infect Dis. 2006;6(8):529-35. DOI: 10.1016/
S1473-3099(06)70553-9 PMID: 16870531
31. Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K,  
et al.  Epidemiology and clinical management of Legionnaires’ 
disease. Lancet Infect Dis. 2014;14(10):1011-21. DOI: 10.1016/
S1473-3099(14)70713-3 PMID: 24970283
License and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate 
credit to the source, provide a link to the licence, and indi-
cate if changes were made.
This article is copyright of the authors, 2017.
